Will Geron Corporation(NASDAQ:GERN), Synta Pharmaceuticals Corp.(NASDAQ:SNTA), and Cerus Corporation(NASDAQ:CERS) Advanced In The Pharamceuticals Game?
New York, NY – GDP INSIDER – 10/17/2014.
This article discusses three pharmaceutical companies: Geron Corporation(NASDAQ:GERN), Synta Pharmaceuticals Corp.(NASDAQ:SNTA), and Cerus Corporation(NASDAQ:CERS)
Geron Corporation(NASDAQ:GERN) has traded within a range of $1.31 to $7.36 over the past 52 weeks and is unfortunately far closer to the former than the latter with a trading price of $2.20. The California-based clinical stage biopharmaceutical company is currently involved in the development of a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company is expected to report its third quarter financial results during the first week of November.
Synta Pharmaceuticals Corp.(NASDAQ:SNTA) is also expected to report its third quarter financial results during the first week of November. This period will mark the first Synta will have been led by Chief Executive Officer Anne Whitaker, who was named to the position on Aug. 6th, 2014. The Massachusetts-based biopharmaceutical discovers, develops, and commercializes small molecule drugs to be used to treat severa medical conditions like cancer and chronic inflammatory disease.
Cerus Corporation(NASDAQ:CERS) currently has a bid price of $4.02 x 2,000 and an offer price of $4.65 x 1,000, figures which suggest that the company’s value may soon fluctuate. Not only that, but the company also had a relatively large trading volume of 1.44 million yesterday. On Oct. 7th, the company revealed that the FDA had accepted Cerus’ clinical protocol to make its INTERCEPT Blood System for platelets available under the Expanded Access Investigational Device Exemption.
HotStockGains.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word BREAKOUT to 555888 from your cell phone.
Additionally, HotStockGains free newsletter provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.
Disclosure: HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://hotstockgains.com/disclaimer/ for complete risks and disclosures.